Incyte Corporation Asset Resilience Ratio
Incyte Corporation asset resilience ratio. Incyte Corporation (INCY) has an Asset Resilience Ratio of 7.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Incyte Corporation defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Incyte Corporation (1999–2025)
Asset resilience ratio of Incyte Corporation from 1999 to 2025. This chart shows how Incyte Corporation's Asset Resilience Ratio has changed over time. Read INCY liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Incyte Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Incyte Corporation asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $553.37 Million | 7.03% |
| Total Liquid Assets | $553.37 Million | 7.03% |
Asset Resilience Insights
- Limited Liquidity: Incyte Corporation maintains only 7.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Incyte Corporation Industry Peers by Asset Resilience Ratio
Compare Incyte Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Incyte Corporation Asset Resilience Ratio by Year (1999–2025)
Incyte Corporation asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Incyte Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.94% | $482.79 Million | $6.96 Billion | -1.70pp |
| 2024-12-31 | 8.64% | $470.26 Million | $5.44 Billion | +2.11pp |
| 2023-12-31 | 6.53% | $442.67 Million | $6.78 Billion | +1.60pp |
| 2022-12-31 | 4.92% | $287.54 Million | $5.84 Billion | -0.97pp |
| 2021-12-31 | 5.89% | $290.75 Million | $4.93 Billion | -2.20pp |
| 2020-12-31 | 8.10% | $288.37 Million | $3.56 Billion | -0.21pp |
| 2019-12-31 | 8.31% | $284.87 Million | $3.43 Billion | -2.06pp |
| 2018-12-31 | 10.37% | $274.34 Million | $2.65 Billion | -1.36pp |
| 2017-12-31 | 11.73% | $270.14 Million | $2.30 Billion | +2.20pp |
| 2016-12-31 | 9.53% | $156.20 Million | $1.64 Billion | -8.96pp |
| 2015-12-31 | 18.50% | $186.34 Million | $1.01 Billion | +0.67pp |
| 2014-12-31 | 17.83% | $147.97 Million | $830.07 Million | +11.86pp |
| 2013-12-31 | 5.97% | $37.58 Million | $629.57 Million | +4.65pp |
| 2012-12-31 | 1.32% | $4.36 Million | $330.42 Million | -0.03pp |
| 2011-12-31 | 1.35% | $4.43 Million | $328.96 Million | +0.07pp |
| 2010-12-31 | 1.28% | $6.26 Million | $489.58 Million | -1.61pp |
| 2009-12-31 | 2.89% | $20.59 Million | $712.39 Million | -5.40pp |
| 2008-12-31 | 8.29% | $19.26 Million | $232.39 Million | -45.24pp |
| 2007-12-31 | 53.53% | $147.58 Million | $275.69 Million | -31.23pp |
| 2006-12-31 | 84.76% | $299.71 Million | $353.60 Million | -4.38pp |
| 2005-12-31 | 89.14% | $333.48 Million | $374.11 Million | +23.83pp |
| 2004-12-31 | 65.31% | $337.58 Million | $516.92 Million | -4.28pp |
| 2003-12-31 | 69.59% | $264.11 Million | $379.55 Million | -3.96pp |
| 2002-12-31 | 73.55% | $406.09 Million | $552.14 Million | +7.71pp |
| 2001-12-31 | 65.84% | $464.54 Million | $705.56 Million | +12.61pp |
| 2000-12-31 | 53.23% | $472.02 Million | $886.82 Million | +37.59pp |
| 1999-12-31 | 15.64% | $34.70 Million | $221.90 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more